FGF2 and small cell lung carcinoma: MG624, an α7nAChR antagonist, reduces nicotine-induced early growth response gene 1 (Egr-1) binding activity to the fibroblast growth factor 2 (FGF2) promoter that inhibits angiogenic effects in SCLC 66.